Неалкогольная жировая болезнь печени у пациенток с синдромом поликистозных яичников

Обложка

Цитировать

Полный текст

Аннотация

В статье представлен обзор современной литературы по проблеме взаимосвязи синдрома поликистозных яичников (СПКЯ) и неалкогольной жировой болезни печени (НАЖБП). Распространенность НАЖБП у женщин, страдающих СПКЯ, значительно выше в сравнении с общей популяцией. Среди причин высокой коморбидности этих заболеваний лежит общность патогенетических путей, включающих инсулинорезистентность, ожирение и метаболический синдром. Формирование НАЖБП у женщин с СПКЯ в более молодом возрасте и более раннее прогрессирование изменений в печени, чем в общей популяции, являются неблагоприятными прогностическими факторами. Представленные результаты собственных наблюдений подтверждают высокую распространенность НАЖБП у пациенток с СПКЯ, ее ассоциированность с ожирением, нарушениями липидного обмена и адипокинов. Применение препаратов женских половых стероидов у пациенток с СПКЯ и НАЖБП сопряжено с риском развития лекарственных реакций со стороны печени и требует контроля состояния печени до начала и на протяжении периода лечения.

Об авторах

Ю. Б Успенская

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

Email: jusp@mail.ru
канд. мед. наук, вед. науч. сотр. научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

И. В Кузнецова

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

д-р мед. наук, проф., гл. науч. сотр. научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Э. Р Ведзижева

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России

аспирант научно-исследовательского отд. женского здоровья НИЦ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2

Список литературы

  1. Буеверов А.О. Возможности лечения лекарственных поражений печени в условиях необходимости приема гепатотоксичных препаратов. Лечащий врач. 2009; 2: 40-2.
  2. Никитин И.Г. Скрининговая программа по выявлению распространенности неалкогольной жировой болезни печени и определению факторов риска развития заболевания. Рос. мед. вести. 2010; 4 (1): 41-6.
  3. Руководство по амбулаторно - поликлинической помощи в акушерстве и гинекологии. Под ред. В.Е.Радзинского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2014.
  4. Руководство по репродуктивной медицине. Под ред. Б.Карра, Р.Блэкуэлла, Р.Азиза. Пер. с англ. М.: Практика, 2015.
  5. Abdelmalek M.F, Diehl A.M. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 2007; 91: 1125-49.
  6. Adams L.A, Lymp J.F, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population - based cohort study. Gastroenterology 2005; 129: 113-21.
  7. Agacayak E, Tunc S.Y, Sak S et al. Levels of Neopterin and other Inflammatory Markers in Obese and Non-Obese Patients with Polycystic Ovary Syndrome. Med Sci Monit 2015; 21: 2446-55.
  8. Alvarez-Blasco F, Botella-Carretero J.I, San Millán J.L, Escobar-Morreale H.F. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166: 2081-6.
  9. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. National Guideline Clearinghouse. Available at http://guideline.gov/summary/summary.aspx?doc_id=7108. Accessed: August 28, 2009.
  10. Angulo P, Alba L.M, Petrovic L.M et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41 (6): 943-9.
  11. Awartani K.A, Cheung A.P. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 2002; 24 (5): 393-401.
  12. Azziz R, Woods K.S, Reyna R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-9.
  13. Azziz R, Dumesic D.A, Goodarzi M.O. Polycystic ovary syndrome: an ancient disorder? Fertil Steril 2011; 95: 1544-8.
  14. Bantel H, Ruck P, Gregor M, Schulze-Osthoff K. Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol 2001; 80: 230-9.
  15. Baranova A, Tran T.P, Afendy A et al. Molecular signature of adipose tissue in patients with both nonalcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med 2013; 11: 133.
  16. Baranova A, Tran T.P, Birerdinc A, Younossi Z.M. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non - alcoholic fatty liver disease. Aliment Pharmacol Ther 2011; 33: 801-4.
  17. Barber T.M, Franks S. Genetics of polycystic ovary syndrome. Front Horm Res 2013; 40: 28-39.
  18. Brower M.A, Jones M.R, Rotter J.I et al. Further investigation in Europeans of susceptibility variants for polycystic ovary syndrome discovered in genome - wide association studies of Chinese individuals. J Clin Endocrinol Metab 2015; 100: 182-6.
  19. Brzozowska M.M, Ostapowicz G, Weltman M.D. An association between non - alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009; 24: 243-7.
  20. Bugianesi E, Gastaldelli A, Vanni E et al. Insulin resistance in non - diabetic patients with non - alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48 (4): 634-42.
  21. Cadranel J.F, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.
  22. Cankaya S, Demir B, Aksakal S.E et al. Insulin resistance and its relationship with high molecular weight adiponectin in adolescents with polycystic ovary syndrome and a maternal history of polycystic ovary syndrome. Fertil Steril 2014; 102: 826-30.
  23. Cerda C, Perez-Ayuso R.M, Riquelme A et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol 2007; 47 (3): 412-7.
  24. Chalasani N, Younossi Z, Lavine J.E et al. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
  25. Chang R.J, Nakamura R.M, Judd H.L, Kaplan S.A. Insulinresistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 1983; 57: 356-9.
  26. Ciotta L, Pagano I, Stracquadanio M, Formuso C. Polycystic ovarian syndrome incidence in young women with non - alcoholic fatty liver disease. Minerva Ginecol 2011; 63: 429-37.
  27. Cusi K, Charlton M, Sanyal A.J. The diagnosis and management of non - alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
  28. Cussons A.J, Watts G.F, Mori T.A, Stuckey B.G. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-8.
  29. Diamanti-Kandarakis E, Christakou C.D. Insulin Resistance in PCOS. Springer, 2009.
  30. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006; 30 (1): 13-7.
  31. Dunaif A, Graf M, Mandeli J et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65: 499-507.
  32. Dunaif A, Segal K.R, Shelley D.R et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41: 1257-66.
  33. Dunaif A. Drug insight: insulin - sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008; 4: 272-83.
  34. Economou F, Xyrafis X, Livadas S et al. In overweight/obese but not in normal - weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009; 8: 199-206.
  35. El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2010; 109: 239-41.
  36. Feldstein A.E, Wieckowska A, Lopez A.R et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009; 50: 1072-8.
  37. Gambarin-Gelwan M, Kinkhabwala S.V, Schiano T.D et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol 2007; 5: 496-501.
  38. Gangale M.F, Miele L, Lanzone A et al. Long - term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) 2011; 75: 520-7.
  39. Gao T, Wu L, Chang F, Cao G. Low circulating ghrelin levels in women with polycystic ovary syndrome: a systematic review and meta - analysis. Endocr J 2016; 63 (1): 93-100.
  40. Gauna C, van der Lely A.J. Somatostatin, cortistatin, ghrelin and glucose metabolism. J Endocrinol Invest 2005; 28: 127-31.
  41. Goldman M.H, Scheraldi C.A, Soule W.C. Ovarian hyperthecosis associated with fatty liver disease. Am J Obstet Gynecol 1987; 156: 1239-40.
  42. Gomez-Meade C.A, Lopez-Mitnik G, Messiah S.E et al. Cardiometabolic health among gastric bypass surgery patients with polycystic ovarian syndrome. World J Diabetes 2013; 4: 64-9.
  43. Gonzalez F, Sia C.L, Bearson D.M, Blair H.E. Hyperandrogenism induces a proinflammatory TNFa response to glucose ingestion in a receptor - dependent fashion. Endocrine J Clin Endocrinol Metab 2016; 51: 211-21.
  44. Goodman N.F, Cobin R.H, Futterweit W et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. Endocr Pract 2015; 21 (11): 1291-300.
  45. Goverde A.J, van Koert A.J, Eijkemans M.J et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009; 24: 710-7.
  46. Harrison S.A, Torgerson S, Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-7.
  47. Jamali R. Non - Alcoholic Fatty Liver Disease. Walter Siegenthaler, 2013.
  48. Kadowaki T, Yamauchi T, Kubota N et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116: 1784-92.
  49. Kauffman R.P, Baker T.E, Baker V et al. Endocrine factors associated with non - alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 2010; 26: 39-46.
  50. Kojima M, Hosoda H, Date Y et al. Ghrelin is a growth - hormone - releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
  51. Kola B, Hubina E, Tucci S.A et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005; 280: 25196-201.
  52. Komarowska H, Wasko R, Iwanik K et al. Ghrelin ovarian cell expression in patients with polycystic ovary syndrome: animmunohistochemical evaluation. Horm Metab Res 2006; 38: 783-8.
  53. Lee Y.H, Pratley R.E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005; 5: 70-5.
  54. Legro R.S, Arslanian S.A, Ehrmann D.A et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98: 4565-92.
  55. Lerchbaum E, Gruber H.J, Schwetz V et al. Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol 2011; 165: 935-43.
  56. Li Y, Hai J, Li L et al. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non - alcoholic fatty liver disease development. Endocrine 2013; 43: 376-86.
  57. Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6 (4): 236-47.
  58. Macut D, Tziomalos K, Božić-Antić I et al. Non - alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016. pii: dew076.
  59. Mao Y, Cheng J, Yu F et al. Ghrelin Attenuated Lipotoxicity via Autophagy Induction and Nuclear Factor-κB Inhibition. Cell Physiol Biochem 2015; 37 (2): 563-76.
  60. March W.A, Moore V.M, Willson K.J et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25: 544-51.
  61. Marchesini G, Brizi M, Morselli-Labate A.M et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107 (5): 450-5.
  62. Mitkov M, Pehlivanov B, Orbetzova M. Serum ghrelin level in women with polycystic ovary syndrome and its relationship with endocrine and metabolic parameters. Gynecol Endocrinol 2008; 24: 625-30.
  63. Murata M, Okimura Y, Iida K et al. Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells. J Biol Chem 2002; 277: 5667-74.
  64. Myers R.P, Fong A, Shaheen A.A. Utilization rates, complications and costs of percutaneous liver biopsy: a population - based study including 4275 biopsies. Liver Int 2008; 28: 705-12.
  65. Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl - ghrelin and it association with non - alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord 2015; 14: 44.
  66. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8.
  67. Nehir Aytan A, Bastu E, Demiral I et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 2016 Mar 7: 1-5.
  68. O’Reilly M.W, Taylor A.E, Crabtree N.J et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014; 99: 1027-36.
  69. Ozturk Z.A, Kadayifci A. Insulin sensitizers for the treatment of nonalcoholic fatty liver disease. World J Hepatol 2014; 6 (4): 199-206.
  70. Panidis D, Tziomalos K, Misichronis G et al. Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2012; 27: 541-9.
  71. Parker H.M, Johnson N.A, Burdon C.A et al. Omega-3 supplementation and non - alcoholic fatty liver disease: a systematic review and meta - analysis. J Hepatol 2012; 56: 944-51.
  72. Pasquali R, Casimirri F, Venturoli S et al. Body fat distribution has weight - independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-13.
  73. Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine minotransferase levels. Ann Intern Med 2002; 137: 1-10.
  74. Preiss D, Sattar N, Harborne L et al. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract 2008; 62: 1337-43.
  75. Qu Z, Zhu Y, Jiang J et al. The clinical characteristics and etiological study of nonalcoholic fatty liver disease in Chinese women with PCOS. Iran J Reprod Med 2013; 11 (9): 725-32.
  76. Ramezani-Binabaj M, Motalebi M, Karimi-Sari H et al. Are women with polycystic ovarian syndrome at a high risk of non - alcoholic Fatty liver disease; a meta - analysis. Hepat Mon 2014; 14 (11): e23235.
  77. Randeva H.S, Tan B.K, Weickert M.O et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012; 33: 812-41.
  78. Rodríguez A, Gómez-Ambrosi J, Catalán V et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes (Lond) 2009; 33: 541-52.
  79. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64: 355-65.
  80. Rosenfield R.L. Clinical review: adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 2013; 98: 3572-83.
  81. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteriaand long - term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.
  82. Saadeh S, Younossi Z.M, Remer E.M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123 (3): 745-50.
  83. Schwimmer J.B, Khorram O, Chiu V, Schwimmer W.B. Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 494-7.
  84. Setji T.L, Holland N.D, Sanders L.L et al. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 1741-7.
  85. Siegelman E.S, Rosen M.A. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21 (1): 71-80.
  86. Sirmans S.M, Pate K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 2013; 6: 1-13.
  87. Syn W.K, Choi S.S, Diehl A.M. Apoptosis and cytokines in non - alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565-80.
  88. Tan S, Bechmann L.P, Benson S et al. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 95: 343-8.
  89. Targher G, Bertolini L, Scala L et al. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-3.
  90. Targher G, Solagna E, Tosi F et al. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 695-700.
  91. Thoma C, Day C.P, Trenell M.I. Lifestyle interventions for the treatment of non - alcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56: 255-66.
  92. Tong J, Prigeon R.L, Davis H.W et al. Ghrelin suppresses glucose - stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 2010; 59: 2145-51.
  93. Toulis K.A, Goulis D.G, Farmakiotis D et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta - analysis. Hum Reprod Update 2009; 15 (3): 297-307.
  94. Tziomalos K, Athyros V.G, Karagiannis A. Non - alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. Curr Vasc Pharmacol 2012; 10: 162-72.
  95. Utzschneider K.M, Kahn S.E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91 (12): 4753-61.
  96. Van der Lely A.J, Tschop M, Heiman M.L, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004; 25: 426-57.
  97. Vassilatou E, Lafoyianni S, Vryonidou A et al. Increased androgen bioavailability is associated with non - alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 2010; 25: 212-20.
  98. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20 (26): 8351-63.
  99. Vernon G, Baranova A, Younossi Z.M. Systematic review: the epidemiology and natural history of non - alcoholic fatty liver disease and non - alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
  100. Wieckowska A, Mc Cullough A.J, Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582-9.
  101. Younossi Z.M, Reyes M.J, Mishra A et al. Systematic review with meta - analysis: non - alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther 2014; 39: 3-14.
  102. Zueff L.F, Martins W.P, Vieira C.S, Ferriani R.A. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 2012; 39 (3): 341-7.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).